We herein report a case of refractory ITP with IgM‐MGUS, who was successfully treated with tirabrutinib, a newly developed BTKi approved for WM, lymphoplasmacytic lymphoma (LPL) and primary central nervous system lymphoma (PCNSL) in Japan. This evidence concerns the gene CD40LG and primary central nervous system lymphoma.